ArticleAnalytical chemistry2025
Plasmon-Enhanced Fluorescence Paper Lateral Flow Strip for Point-of-Care Testing of SARS-CoV-2 Antigens.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiplexed plasmon-enhanced lateral flow assay for early diagnosis of acute kidney injury.Biosensors & bioelectronics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Currently commercial colorimetric paper lateral flow immunoassays exhibit insufficient limit of detection (LOD) and limited clinical sensitivity toward the detection of SARS-CoV-2 antigens, which causes a high false negative rate. To mitigate this issue, a new plasmon-enhanced fluorescence probe was developed for paper lateral flow strips (PLFSs). The probe is made of a sandwich-structured Ag-core@silica@dye@silica-shell nanoparticle in which fluorescent dyes are sandwiched between the plasmonic Ag core and the silica outer shell, and the separation distance between the Ag core and the dye molecules is controlled by the silica space layer. At the optimal thickness of the silica space layer, plasmons can amplify fluorescence signals via the Purcell effect. The PLFS with the optimized plasmonic fluorescence probes exhibits a LOD of 65.0 pg/mL toward detection of the SARS-CoV-2 nucleocapsid protein in a buffer solution, which is much lower than that (2.3 ng/mL) of the commercial colorimetric counterpart. Furthermore, it has been used successfully for testing COVID-19 clinical samples, which has achieved 100% clinical sensitivity and 94.2% specificity, while the commercial colorimetric PLFS exhibits 75.7% sensitivity and 91.4% specificity. The results demonstrate that the plasmonic fluorescence PLFS can reduce false negative results significantly. This device has great potential in helping with timely medical intervention and prevention from COVID-19 transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.